000963 华东医药
已收盘 07-08 15:00:00
资讯
新帖
简况
华东医药（000963）披露控股股东部分股份质押及解除质押公告，7月1日股价上涨5.16%
证券之星 · 07-01
华东医药（000963）披露控股股东部分股份质押及解除质押公告，7月1日股价上涨5.16%
华东医药：芮妥欣®铺货推进符合前期规划
证券之星 · 07-01
华东医药：芮妥欣®铺货推进符合前期规划
华东医药：目前公司暂无自愿披露2026年半年度业绩预告的相关安排
证券之星 · 07-01
华东医药：目前公司暂无自愿披露2026年半年度业绩预告的相关安排
华东医药：HDM2017的单药概念验证初步临床数据预计今年第四季度读出
证券之星 · 07-01
华东医药：HDM2017的单药概念验证初步临床数据预计今年第四季度读出
华东医药：本次集采最终影响存在不确定性
证券之星 · 06-30
华东医药：本次集采最终影响存在不确定性
6月29日华东医药涨8.75%，创新药ETF银华基金重仓该股
证券之星 · 06-29
6月29日华东医药涨8.75%，创新药ETF银华基金重仓该股
华东医药（000963）披露全资子公司获得药物临床试验批准通知书，6月25日股价下跌1.27%
证券之星 · 06-25
华东医药（000963）披露全资子公司获得药物临床试验批准通知书，6月25日股价下跌1.27%
华东医药最新公告：全资子公司注射用HDM2017获临床试验批准
证券之星 · 06-25
华东医药最新公告：全资子公司注射用HDM2017获临床试验批准
华东医药：全资子公司获得注射用HDM2005药物临床试验批准通知书
格隆汇 · 06-24
华东医药：全资子公司获得注射用HDM2005药物临床试验批准通知书
华东医药最新公告：全资子公司皮肤治疗仪V30获批上市
证券之星 · 06-24
华东医药最新公告：全资子公司皮肤治疗仪V30获批上市
股市必读：华东医药（000963）6月16日董秘有最新回复
证券之星 · 06-17
股市必读：华东医药（000963）6月16日董秘有最新回复
华东医药：公司目前暂无BTK-PROTAC 管线推进计划
证券之星 · 06-16
华东医药：公司目前暂无BTK-PROTAC 管线推进计划
华东医药：您可在药物临床试验登记与信息公示平台查询DR10624治疗重度高甘油三酯血症的三期临床研究登记信息（登记号
证券之星 · 06-16
华东医药：您可在药物临床试验登记与信息公示平台查询DR10624治疗重度高甘油三酯血症的三期临床研究登记信息（登记号
华东医药(000963.SZ)：注射用聚己内酯微球面部填充剂医疗器械注册申请获受理
智通财经 · 06-09
华东医药(000963.SZ)：注射用聚己内酯微球面部填充剂医疗器械注册申请获受理
华东医药：公司应收账款随销售收入的增长相应增加这是正常现象
证券之星 · 06-04
华东医药：公司应收账款随销售收入的增长相应增加这是正常现象
华东医药：将于2026年6月ADA大会口头报告HDM1002二期临床研究结果
证券之星 · 06-04
华东医药：将于2026年6月ADA大会口头报告HDM1002二期临床研究结果
华东医药：今年公司肿瘤管线的数据读出将主要集中在今年下半年
证券之星 · 05-27
华东医药：今年公司肿瘤管线的数据读出将主要集中在今年下半年
华东医药：次要终点指标包含LSM相对基线的变化、纤维化生物标志物等
证券之星 · 05-27
华东医药：次要终点指标包含LSM相对基线的变化、纤维化生物标志物等
华东医药：正和相关部门保持沟通
证券之星 · 05-27
华东医药：正和相关部门保持沟通
华东医药：市值管理以夯实基本面为核心
证券之星 · 05-27
华东医药：市值管理以夯实基本面为核心
加载更多
公司概况
公司名称：
华东医药股份有限公司
所属行业：
零售业
上市日期：
2000-01-27
主营业务：
华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。
发行价格：
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":28.93,"timestamp":1783494228000,"preClose":29.23,"halted":0,"volume":17311626,"delay":0,"changeRate":-0.0103,"floatShares":1753000000,"shares":1754000000,"eps":1.9968,"marketStatus":"已收盘","change":-0.3,"latestTime":"07-08 15:00:00","open":29.3,"high":29.81,"low":28.92,"amount":507000000,"amplitude":0.0304,"askPrice":28.94,"askSize":47,"bidPrice":28.93,"bidSize":786,"shortable":0,"etf":0,"ttmEps":1.9968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783560600000},"marketStatusCode":5,"adr":0,"adjPreClose":29.23,"symbolType":"stock","openAndCloseTimeList":[[1783474200000,1783481400000],[1783486800000,1783494000000]],"highLimit":32.15,"lowLimit":26.31,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":1.99,"roa":"--","peRate":14.488181,"roe":"3.97%","epsLYR":1.9484,"committee":0.853867,"marketValue":50736000000,"turnoverRate":0.0099,"status":1,"floatMarketCap":50715000000},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2648854151","title":"华东医药（000963）披露控股股东部分股份质押及解除质押公告，7月1日股价上涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648854151","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648854151?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:30","pubTimestamp":1782916235,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，华东医药报收于29.57元，较前一交易日上涨5.16%，最新总市值为518.58亿元。近日，华东医药股份有限公司发布公告，控股股东中国远大集团有限责任公司将其持有的22,500,000股公司股份质押给中国中金财富证券有限公司，用于续贷质押。同时，远大集团解除质押16,330,000股。本次质押及解除质押后，远大集团累计质押股份为144,810,000股，占其所持股份比例19.81%，占公司总股本比例8.26%。已质押股份无限售和冻结情况，未质押股份也无限制情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","000963","BK0175","LU2328871848.SGD","BK0183","BK0196","BK0188","BK0132","LU1969619763.USD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515126","title":"华东医药：芮妥欣®铺货推进符合前期规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515126","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515126?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:24","pubTimestamp":1782894254,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药07月01日在投资者关系平台上答复投资者关心的问题。芮妥欣作为公司重点医美产品，自上市以来市场关注度较高。芮妥欣铺货推进符合前期规划，依托成熟医美渠道已快速覆盖全国主流连锁医美机构，下半年将逐步放量。终端机构对其重组技术差异化优势认可度高，用户口碑稳步提升。后续公司将持续开展全国专家学术会、规范化实操培训，持续夯实产品学术壁垒，协同全品类医美矩阵扩大市场覆盖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0175","BK0188","LU2328871848.SGD","BK0187","BK0183","000963","BK0132","BK0196","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648951543","title":"华东医药：目前公司暂无自愿披露2026年半年度业绩预告的相关安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2648951543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648951543?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:24","pubTimestamp":1782894250,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，结合公司经营情况，市场普遍预判半年报业绩变动幅度大概率未达到深交所强制披露业绩预告的标准。想咨询公司：即便无强制披露要求，管理层是否会考虑自愿发布2026年半年度业绩预告，提前向投资者反馈医美、GLP-1、创新药等板块上半年经营情况？感谢解答。华东医药回复：您好！目前公司暂无自愿披露2026年半年度业绩预告的相关安排。关于半年度业绩的详细情况，敬请关注公司后续披露的正式定期报告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","000963","BK0196","BK0183","BK0175","BK0209","LU2328871848.SGD","LU1969619763.USD","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515435","title":"华东医药：HDM2017的单药概念验证初步临床数据预计今年第四季度读出","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515435?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:24","pubTimestamp":1782894248,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！我想问的是注射用 HDM2017 晚期恶性实体瘤适应症的临床试验一期结果什么时候公布？是在学术会议期间发布还是以公告的形式发布？谢谢！华东医药回复：您好！HDM2017的单药概念验证初步临床数据预计今年第四季度读出。后续公司将结合项目进展，择机通过国际权威学术会议、公司公告或官方新闻等渠道对外披露相关数据，相关信息敬请持续留意公司后续发布内容。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0132","000963","BK0183","BK0187","BK0209","LU1969619763.USD","BK0196","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647852585","title":"华东医药：本次集采最终影响存在不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2647852585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647852585?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:01","pubTimestamp":1782781266,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：占公司仿制药板块销售额过半的几款核心产品都进入十二批集采，公司怎么考虑，会对27年的收入产生多大影响华东医药回复：您好！本次集采最终影响取决于具体竞价规则、公司产品是否中标及中标价格、约定采购量、竞争格局等因素，存在不确定性，目前尚无法预判对收入的具体影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000008885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","LU1969619763.USD","BK0188","BK0183","BK0196","LU2328871848.SGD","BK0132","BK0175","BK0187","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322635","title":"6月29日华东医药涨8.75%，创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322635?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:48","pubTimestamp":1782722939,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日华东医药涨8.75%，收盘报28.72元，换手率2.16%，成交量37.94万手，成交额10.52亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共45家，其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0183","LU2328871848.SGD","BK0187","BK0175","BK0188","LU1969619763.USD","159316","BK0196","BK0132","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646809345","title":"华东医药（000963）披露全资子公司获得药物临床试验批准通知书，6月25日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646809345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646809345?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:17","pubTimestamp":1782397035,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，华东医药报收于27.89元，较前一交易日下跌1.27%，最新总市值为489.12亿元。近日，华东医药披露公告显示，2026年6月24日，公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用HDM2017联合治疗晚期结直肠癌的临床试验申请获得批准。该药此前已获中国和美国临床试验批准，部分适应症获FDA孤儿药资格认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","LU1969619763.USD","BK0187","BK0209","000963","LU2328871848.SGD","BK0183","BK0132","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646901871","title":"华东医药最新公告：全资子公司注射用HDM2017获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2646901871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646901871?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:19","pubTimestamp":1782382793,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司杭州中美华东制药有限公司收到国家药监局核准签发的《药物临床试验批准通知书》，注射用HDM2017联合治疗晚期结直肠癌的临床试验申请获得批准。该药物为靶向钙黏蛋白17的新型抗体药物偶联物，此前已获中美两国晚期恶性实体瘤适应症临床试验批准及美国FDA三项孤儿药资格认定。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500033918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0187","BK0188","BK0183","BK0196","LU2328871848.SGD","BK0209","LU1969619763.USD","BK0132","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891765","title":"华东医药：全资子公司获得注射用HDM2005药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891765","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645891765?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:11","pubTimestamp":1782295883,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["000963","BK0187","BK0183","BK0209","BK0132","BK0196","LU1969619763.USD","BK0175","BK0188","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891036","title":"华东医药最新公告：全资子公司皮肤治疗仪V30获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891036","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645891036?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:11","pubTimestamp":1782295870,"startTime":"0","endTime":"0","summary":"华东医药公告称，公司全资子公司Viora收到国家药监局签发的《医疗器械注册证》，其三类医疗器械皮肤治疗仪V30获批上市。V系列产品兼容性强，可适配未来Viora开发的新技术。V30已获得美国FDA、欧盟CE注册认证。同系列产品V20已于2024年9月获得NMPA批准上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400034269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK0187","LU1969619763.USD","BK0175","000963","BK0196","BK0209","BK0188","BK0183","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644761998","title":"股市必读：华东医药（000963）6月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644761998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644761998?lang=zh_cn&edition=full","pubTime":"2026-06-17 01:16","pubTimestamp":1781630170,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，华东医药报收于28.26元，下跌2.55%，换手率0.68%，成交量11.99万手，成交额3.41亿元。董秘最新回复投资者： 公司年报里就披露10624在临床三期中，怎么都过去一个多月了，还没看到三期临床的注册信息呢董秘： 您好！控股子公司道尔生物专注基于多结构域的多特异性生物药的创新开发，依托自有技术平台差异化布局创新ADC。当日关注点交易信息汇总：6月16日主力资金净流出3477.84万元，散户资金净流入3881.89万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700000514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0183","LU2328871848.SGD","LU1969619763.USD","BK0209","BK0188","BK0196","BK0132","BK0187","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643445737","title":"华东医药：公司目前暂无BTK-PROTAC 管线推进计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2643445737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643445737?lang=zh_cn&edition=full","pubTime":"2026-06-16 16:36","pubTimestamp":1781598969,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问：罗氏重金买了一款btk protac，公司几年前就曾披露了同靶点同机制的管线，但还没推进到临床，请问公司后续还会推进吗，如果推进，预计什么时候IND；如果不推进，公司是作何考虑华东医药回复：您好！公司目前暂无BTK-PROTAC 管线推进计划。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600028946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0196","LU1969619763.USD","LU2328871848.SGD","BK0175","BK0188","BK0209","000963","BK0183","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643737969","title":"华东医药：您可在药物临床试验登记与信息公示平台查询DR10624治疗重度高甘油三酯血症的三期临床研究登记信息（登记号","url":"https://stock-news.laohu8.com/highlight/detail?id=2643737969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643737969?lang=zh_cn&edition=full","pubTime":"2026-06-16 16:33","pubTimestamp":1781598786,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问：公司年报里就披露10624在临床三期中，怎么都过去一个多月了，还没看到三期临床的注册信息呢华东医药回复：您好！您可在药物临床试验登记与信息公示平台查询DR10624治疗重度高甘油三酯血症的三期临床研究登记信息（登记号：CTR20262269）。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600028818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0196","BK0187","BK0183","BK0132","BK0209","LU2328871848.SGD","LU1969619763.USD","BK0188","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642150468","title":"华东医药(000963.SZ)：注射用聚己内酯微球面部填充剂医疗器械注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2642150468","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642150468?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:15","pubTimestamp":1780992909,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 华东医药 发布公告，2026年6月8日，公司全资子公司欣可丽美学(杭州)供应链管理有限公司收到国家药品监督管理局签发的《受理通知书》，其代理申报的三类医疗器械注射用聚己内酯微球面部填充剂Ellansé伊妍仕S型拓展新适用症的变更注册申请获得受理，本次申请新增适用症：用于额部皮下或骨膜上植入，以改善中至重度额部轮廓缺陷。公司后续将继续全力开展这款产品在中国的注册工作，推动其新适用症早日获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0209","LU1969619763.USD","BK1100","BK0175","BK0188","BK1574","BK0196","BK0132","159883","BK0183","BK0187","000963","LU2328871848.SGD","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640335011","title":"华东医药：公司应收账款随销售收入的增长相应增加这是正常现象","url":"https://stock-news.laohu8.com/highlight/detail?id=2640335011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640335011?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:06","pubTimestamp":1780535165,"startTime":"0","endTime":"0","summary":"您问题中提及的数字经判断主要涉及公司财务报告中应收账款事项。公司应收账款金额主要和医药商业业务相关，因医药商业销售主要客户为浙江省内各大公立医院，销售回款存在一定账期，这是由医药商业的业务模式决定的，也在财报数据中得到反映。公司应收账款随销售收入的增长相应增加这是正常现象。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0183","BK0175","BK0188","BK0196","LU2328871848.SGD","BK0187","BK0132","BK0209","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133361","title":"华东医药：将于2026年6月ADA大会口头报告HDM1002二期临床研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133361?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:03","pubTimestamp":1780534989,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：1002的降糖二期结束这么久了，数据还不公布吗华东医药回复：您好！公司将于2026年6月举行的美国糖尿病协会（ADA）大会上以口头报告的方式展示HDM1002糖尿病适应症二期临床研究结果。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","000963","BK0175","BK0188","BK0183","LU1969619763.USD","LU2328871848.SGD","BK0196","BK0209","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638357408","title":"华东医药：今年公司肿瘤管线的数据读出将主要集中在今年下半年","url":"https://stock-news.laohu8.com/highlight/detail?id=2638357408","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638357408?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:06","pubTimestamp":1779865581,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：ASCO会议，公司连一个像样点的临床/临床前阶段的数据都拿不出来吗，不知道研发费用都花哪儿去了，很难想象公司的肿瘤管线还占了公司所有管线近半数之多，不如把研发费用集中到代谢领域华东医药回复：您好！今年公司肿瘤管线的数据读出将主要集中在今年下半年。感谢您的关注！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700024516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0209","BK0132","BK0187","LU1969619763.USD","000963","BK0196","BK0175","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574073","title":"华东医药：次要终点指标包含LSM相对基线的变化、纤维化生物标志物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638574073?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:06","pubTimestamp":1779865580,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：dr10624的mash二期临床设计，终点指标并没有核心指标纤维化逆转数据，请问公司作何考虑。目前正在开展的DR10624用于代谢相关脂肪性肝病的Ⅱ期临床研究，次要终点指标包含LSM相对基线的变化、纤维化生物标志物等，可提示肝纤维化是否得到改善、是否存在逆转趋势。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700024511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","LU1969619763.USD","BK0187","BK0209","000963","LU2328871848.SGD","BK0183","BK0132","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638573550","title":"华东医药：正和相关部门保持沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2638573550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638573550?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:34","pubTimestamp":1779852857,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。根据国家组织药品联合采购办公室发布的相关公告，已公布的为新批次集采预填报药品目录，新批次国家药品集中采购品种最终范围、企业投标资质要求等，以后续发布的采购公告为准。公司就子公司纳入此次预填报目录的部分品种正和相关部门保持沟通。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","000963","BK0175","BK0209","LU1969619763.USD","BK0188","BK0183","LU2328871848.SGD","BK0132","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638735895","title":"华东医药：市值管理以夯实基本面为核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2638735895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638735895?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:34","pubTimestamp":1779852856,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。市值管理以夯实基本面为核心，同时规范披露、加强资本市场沟通，传递公司价值。创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程。未来如达成明确合作协议，公司将严格按照信息披露规则履行披露义务。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","000963","BK0175","LU2328871848.SGD","BK0183","BK0196","BK0188","BK0132","LU1969619763.USD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783501502341,"stockEarnings":[{"period":"1week","weight":0.0395},{"period":"1month","weight":0.0503},{"period":"3month","weight":-0.1766},{"period":"6month","weight":-0.2356},{"period":"1year","weight":-0.2407},{"period":"ytd","weight":-0.2434}],"compareEarnings":[{"period":"1week","weight":-0.0254},{"period":"1month","weight":-0.0093},{"period":"3month","weight":-0.0012},{"period":"6month","weight":-0.0227},{"period":"1year","weight":0.1489},{"period":"ytd","weight":0.0054}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"84304人(较上一季度增加26.48%)","perCapita":"20793股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":" 华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}